NCT04131036View on ClinicalTrials.gov

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Hemophilia A
Interventions
OTHER

assessment of joint health and bone density

We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.

Trial Locations (4)

78229

RECRUITING

The University of Texas Health Science Center at San Antonio, San Antonio

90007

NOT_YET_RECRUITING

Orthopedic Hemophilia Treatment Center, Los Angeles

92092

RECRUITING

Hemophilia and Thrombosis Treatment Center, University of California, San Diego, San Diego

98101

RECRUITING

Washington Center for Bleeding Disorders at Washington Institute for Coagulation, Seattle

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Washington Institute for Coagulation

OTHER